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INTRODUCTION
Although structurally and functionally very diverse, glycoproteins, glycolipids, gly-
cosyl phosphatidyl-inositol (GPI) anchors and proteoglycans, jointly called glycoconju-
gates, share one common feature – they all bear oligosaccharide chains (glycans) within
their structure. Glycans are the most abundant and the most diverse biopolymers in na-
ture. Due to their enormous structural diversity, oligosaccharide chains are ideal media
for coding biological information. Their attachment affects many properties of glycoco-
njugates, such as folding, secretion, biomolecular interactions, serum lifetime and many
others. Based on the highly specific interactions between glycans and their physiological
receptors – lectins, glycoconjugates participate in many crucial biological processes such
as cell-cell and cell-matrix interactions, adhesion, signaling, differentiation and develop-
ment. Placed mainly on the outer surface of the cells, glycans may serve as identification
molecules to the surrounding world (1). They mark cells and tissues as 'self' and send
signals to the immune system when tissue is injured. On the other hand, tumor cells and
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viruses use glycans on their surfaces to slip past the immune system. Many pathogens
use specific glycan structures of the host-cell membrane glycoconjugates to stick onto
the host cells and to spread themselves to the surrounding cells. Some inflammatory re-
actions are triggered by carbohydrates and many diseases are associated with changes
in glycan structures (2). All these processes are potential targets for therapeutic interven-
tion and this is why carbohydrate-based drugs are increasingly being taken up by the
modern biotechnology and pharmaceutical industry (3).
The basic principle of glycosylation, i.e., the lack of template, makes it inherently
sensitive to all changes within the cell, and glycan structures that are being produced at
any moment actually mirror all relevant past events in the cell (4). Nearly a decade ago
we hypothesized that these characteristics make glycosylation a very good candidate for
an important role in the stress response (5). In the meantime, we have gathered a signifi-
cant pool of evidence to support this hypothesis. Initially, we identified changes in lect-
ins in livers of rats exposed to stress (6, 7), and subsequently we also identified altered
glycosylation profiles both in humans exposed to war-stress (8–10), and in in vitro mod-
els of stress (11, 12). Galectin-3 was found to be particularly interesting since different
types of stress had different effects on this lectin (13, 14). We were able to demonstrate
that regulation of galectin-3 proceeds through NF-kB, which places it downstream from
corticosteroids (and CRF) in the stress response (15). Finally, we were also able to de-
monstrate specific stress-induced changes in the activity of sialyltransferases (16). Very
recently, we were also able to show that gangliosides and GPI-anchored proteins can
spontaneously move between different cells (17), which might be an important signaling
mechanism.
In 1990’s, a series of simple carbohydrate based drugs failed clinical trails mostly
because of inadequate binding constants for targeted receptors. Structural complexity of
branched carbohydrate chains makes them difficult to analyze and hard to produce, but
new automated methods promise a dramatic change and compounds based on complex
carbohydrates are now in clinical trials for many diseases (18).
Therapeutic glycoproteins and proteoglycans
One of the most important groups of biotechnology products are therapeutic gly-
coproteins (19). Many important glycoprotein therapeutics have been expressed using
various production vehicles, for example, cell lines, transgenic animals and plants (20).
In precisely optimized glycosylation processes, proteins are bristled with sugars, which
ensures that these molecules will remain in circulation long enough to achieve their pur-
pose. These include the top-selling protein drugs erythropoietin (EPO), granulocyte macro-
phage-colony stimulating factor, and tissue plasminogen activator. Maybe the best-studied
example is the red blood cell booster erythropoietin which interacts with a membrane-
-signal-transducing receptor and induces proliferation and differentiation of erythroid
progenitors. The fact that recombinant erythropoietin has annual worldwide sales of
nearly 5 billion US dollars is more than an indication of its importance and value in mo-
dern medicine. For over a decade, recombinant EPO has had a significant role in treating
anemias caused by bone marrow suppression and end-stage renal disease (21).
EPO carries four sialylated complex-type N-glycans. In vivo activity of deglycosy-
lated EPO is less than 10% of glycosylated EPO because incompletely glycosylated forms
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are rapidly cleared by filtration in the kidney and through the action of Gal/GlcNAc/Man
receptors in hepatocytes and macrophages (22, 23). This shows that glycans can have
dramatic effects on the properties of glycoprotein-drugs, and that the control of glycosy-
lation during their production is very important. This is why achieving proper glycosy-
lation has become one of the major challenges in biotechnology. Indeed, the identification
and cloning of relevant glycosyltransferases and the ability to modulate their expres-
sion, as well as use of appropriate cell lines or culture conditions, are important in this
respect. For instance, siRNA (small interfering RNA) and knock-out strategies have been
recently used to reduce core fucosylation of IgG produced by CHO cells (24, 25). There
are also many other CHO cell lines (Lec and Lec mutants) with altered glycosylation,
while extending the glycosyltransferases repertoire of insect cells has been used to gen-
erate transgenic Sf9 cells with mammalian-type glycosylation.
The technology that uses glycosyltransferases to add sugar nucleotides to carbohy-
drate chains of the glycoprotein-drugs after they have been secreted from the produc-
tion cells was developed under the brand name GlycoAdvance (19). One of the best ex-
amples is the second-generation erythropoietin – darbepoetin alpha. Two extra N-linked
oligosaccharide chains extend the Novel Erythropoiesis Stimulating Protein half-life three
times, permitting a less frequent dosage regime (26).
Another multi-billion dollar carbohydrate drug category is heparin and its deriva-
tives used in the treatment of thrombosis and other cardiovascular indications. Heparins
are currently produced from pig intestines. Unfractioned heparin has been used for sev-
eral decades as an anticoagulant. Its effects are based on the activation of antithrombin,
which leads to the inhibition of thrombin and factor Xa, thus preventing the production
of fibrin clots. Unfortunately, unfractioned heparin can bind to several plasma, platelet,
and endothelial proteins, thereby producing a highly variable anticoagulant response.
Low-molecular mass heparins are now replacing unfractioned heparins because they
have better pharmacological properties and fewer secondary complications than unfrac-
tioned heparin (27). Enzymes of heparin biosynthesis are now being cloned and hence it
should become possible to produce recombinant heparins as well.
Inflammation interrupters
In the late 1980s, several groups of researchers independently cloned the genes for
three human selectins, carbohydrate-binding proteins (lectins) that play an important
role in attracting leucocytes to injured sites in the body, thus promoting inflammation
(28). These proteins are present on the surface of the endothelial cells of blood vessels
when injured tissues release cytokines. In the early 1990s, it was shown that selectins
recognize variants of the carbohydrate structure called Lewis x (Fig. 1), which can be
found on the surface of circulating leukocytes (29). This binding slows down leukocyte
circulation in the bloodstream and facilitates initiation of the inflammatory response.
Although Varki and coworkers showed that blocking L-selectin from binding to sia-
lyl Lewis x (sLex) in mice reduced inflammatory response, their selectin inhibitors failed
to work in animal disease models, so the project was discontinued.
Other researchers from the pharmaceutical industry have also developed an inhibi-
tor of selectins that should work after a heart attack, stroke or tissue transplantation, but
in final-stage of clinical trials data showed that there is no benefit of this drug. Now, in-
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dustry researchers are trying to do better with a recombinant form of P-selectin glyco-
protein ligand-1 (PSGL-1); it binds to P-selectin expressed on the endothelial cells and
on the platelet cells, causing them to stick to leukocytes and create blood clots. By inhib-
iting these selectins they hope to prevent ischemia reperfusion injury and clotting events
that can re-occlude an artery. P-selectin glycoprotein ligand-1 is a 240 kDa homodimer
consisting of two 120 kDa polypeptide chains. The O-linked glycans displayed on PSGL-
-1 must undergo two specific post-translation modifications to enable PSGL-1 to func-
tion as a P-selectin receptor: a(1,3) fucosylation and a(2,3) sialylation (18). A new tech-
nology, called GlycoAdvance, will be used to develop an improved production system
for the biopharmaceutical compound rPSGL-Ig, the P-selectin antagonist that is being
developed to treat inflammation and thrombosis associated with acute coronary syndro-
me and reperfusion injury. It is currently in Phase II clinical trials in patients treated for
heart attack and this technology is being evaluated for use in the production of rPSGL-Ig
for Phase III clinical trials and commercial launch.
Based on the structures of sialyl-Lea and sialyl-Lex, a glycomimetic inhibitor for E-
-selectin was synthesized (30, 31). Smaller in size and more hydrophobic than sialyl-Lex,
it inhibits E-selectin 1,000 times better than sialyl-Lex in an E-selectin mediated cell ad-
hesion assay (32). Another selectin inhibitor, called TBC1269, was also successful in ani-
mal models of asthma and renal failure (33, 34) but did not attenuate asthmatic response
in humans (35), possibly due to the different role of selectins in acute allergic inflamma-
tion in animal models than in human asthma or due to inadequate dosage.
Cancer therapy and vaccines
Several glycans, on both the tumor surface and host elements, have now been iden-
tified as mediating key pathophysiological events during the various steps of tumor
progression, and many new therapeutic strategies are targeting these molecules (36).
Selectin inhibitors can also be used in the therapy of malignant diseases. Metastasing
malignant cells are able to bind to P-selectin on platelets, thus creating a kind of protec-
tive shield against the immune system cells. It was shown that heparin could bind to
P-selectin on platelets and in that way prevent cancer cells from doing the same (37). Be-
cause of the problems heparin can cause in blood coagulation, it cannot be widely used
as a chemotherapeutic agent, but other P-selecting inhibitors may possibly be more ef-
fective.
Inhibiting selectins is not the only way carbohydrates can contribute to the antican-
cer battle. They can be also used as cancer vaccines. Transformed tumor cells escape the
immune system by exposing specific glycolipids and glycoproteins on their surfaces.
This fact has opened a way to the use of carbohydrate chains from these glycomolecules
as vaccines. Some cancer vaccines are undergoing clinical tests. One of them is a syn-
thetic carbohydrate molecule created by Danishefsky (38, 39). First, he synthesized glo-
bo H, a complex hexasaccharide found in high numbers on the surface of many cancer
cells, such as the prostate and breast cancer cells. Many cancer cell antigens, including
globo H, are too small to provoke an immune response, but if the cancer specific antigen
is attached to a molecule the immune system recognizes as foreign, the immune system
can make antibodies against it. Those antibodies can then destroy any cancer cells left in
bloodstream after the treatment of a primary tumor. The vaccine based on the globo H
22
O. Gornik et al.: Glycoscience – a new frontier in rational drug design, Acta Pharm. 56 (2006) 19–30.
antigen gave promising results when tested as an anticancer vaccine in patients with
early prostate cancer. Phase I clinical trial in metastatic breast cancer patients has shown
that fully synthetic globo H conjugate could be a good component of a polyvalent vac-
cine containing several other antigens (40). Danishefsky and Lloyd developed a similar
vaccine for ovarian cancer patients (41). This vaccine is based on the carbohydrate anti-
gen known as Lewis Y, which is present on the surface of ovarian, breast and prostate
cancer cells.
Another antigen present on cancer cells and suitable for vaccine development is
mucin, MUC-1. The mucins, normally expressed by secretory epithelial cells, are present
in cancer cells with significant quantitative and qualitative changes in glycosylation (42).
MUC-1 contains short carbohydrate chains such as Tn [GalNAc(a1-Ser/Thr)], sialyl Tn
and the Thomsen-Friedrenreich antigen [Gal(b1–3)GalNac(a1-Ser/Thr)], which are not
present on normal mucins (43). A conjugate of sialyl Tn with hemocyanin (immune ad-
juvant keyhole limpet) has been tested on breast cancer patients and in combination
with cyclophosphamide gave good results (42).
Some other vaccines based on ganglioside immunogens present on certain types of
cancer cells were investigated as well. Technologies for the manufacture of gangliosides
for use as active pharmaceutical ingredients in cancer vaccines were developed. One of
the cancer vaccine candidates has been tested on patients with melanoma. Another can-
didate has been developed for the treatment of a variety of other malignant diseases, in-
cluding colorectal cancer, lymphoma, small cell lung cancer, sarcoma, gastric cancer and
neuroblastoma (44). All these investigations showed encouraging results, but it is un-
likely that cancer vaccines will be able to cure cancer on their own, but they will proba-
bly be components of a multi therapeutic approach, adjuvant therapy in early-stage dis-
eases or combined with adjuvant chemotherapy (45).
Vaccines based on specific glycoconjugates and lectins are of scientific and commer-
cial interest, not only against cancer, but also as anti-protozoan and anti-viral vaccines.
For instance, the galactose binding lectin of the protozoan Entamoeba histolytica (46) and
hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric
gp120, as novel antigens for HIV vaccine design (47), are also targets being considered
by academic and especially industrial pharmaceutical research groups.
Inhibitors of pathogenic microbes and toxins
Many infectious diseases are initiated by binding of surface lectins of pathogenic or-
ganisms to complementary surface carbohydrates of host tissues. An understanding of
these interactions becomes increasingly important since microbial resistance to antibiot-
ics becomes a more and more acute problem (48). Many potentially deadly bacteria can
evade the majority of antibiotics we rely on. The best way of preventing this is to intro-
duce new medications when the old ones no longer work. The idea is that, instead of
looking for factors that kill bacteria or halt their reproduction, we should look for com-
pounds that interfere with bacterial adhesion. Knowing the principle of adhesion, it can
be predicted that soluble glycans or glycan mimics could be used to block the initial at-
tachment of microbes and toxins to cell surfaces, thus preventing or suppressing the in-
fection (49) (Fig. 1). Because many of these bacteria gain access through airways or gut,
the carbohydrate-based drugs can be delivered orally or bronchially without needing to
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be distributed systemically. These anti-adhesion carbohydrate therapies may be consid-
ered mild, gentle and safer as compared to the present chemotherapy approaches. Car-
bohydrates are ideal for these interventions since they are unlikely to be toxic or immu-
nogenic and many of those which inhibit bacterial adhesion are normal constituents of
cell surfaces or body fluids, especially of human milk (50, 51). It was shown that soluble
carbohydrates recognized by the bacterial lectins block the adhesion of bacteria to ani-
mal cells in vitro. This has also been shown in different mammals such as mice, rabbits,
calves and monkeys. However, in phase II clinical trials the pentasaccharide, shown to
be acting as an anti-adhesive against Streptococcus pneumoniae and Hemophilus influenzae
in vitro, failed to protect young children from nasopharyngeal colonization and, thus,
did not prevent the development of otitis media (50). Possible explanations for this ob-
servation include the fact that the drug was delivered by a nasal spray, that bacteria can
express multiple specificities (so the inhibition may require a cocktail of oligosaccharides),
and the fact that children may have different carbohydrate receptors than adults. How-
ever, recent receptor binding studies disclose a novel class of high-affinity inhibitors of
the Escherichia coli FimH adhesion , and there is still good reason to believe that this kind
of anti-microbial therapy has a bright future.
It has also been suggested that compounds affecting glycosylphosphatidylinositol
(GPI) biosynthesis in the bloodstream form of Trypanosoma brucei should be trypanocidal
(53). Thus, the GPI biosynthetic pathway was a potential drug target against African hu-
man sleeping sickness. Scientists have described cell-permeable analogues of a GPI in-
termediate that are toxic to this parasite but not to human cells.
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Fig. 1. Schematic representation of the interference of therapeutics with adhesion of pathogenic
bacteria in order to prevent infection.
Treatment of lysosomal storage diseases
There are approximately fifty known lysosomal storage diseases that afflict humans.
These rare diseases are caused by mutations that result in inactive or missorted enzymes,
leading to the accumulation of particular substances in lysosomes. The effective treat-
ment for these diseases is based on the ability to compensate the missing enzyme activity.
This treatment can be effective only if the enzymes are properly targeted at the lysosomes
(54). A good example of successful targeting, both with recombinant and extracted en-
zymes, is the glucocerebrosidase replacement therapy of Gaucher’s disease (55, 56). This
most common lysosomal storage disorder is caused by the defective activity of acid-ß-
-glucosidase leading to accumulation of glucosylceramide, particulary in cells of the
macrophage lineage (57). Uptake of the enzyme in replacement therapy is achieved by
remodeling its oligosaccharide chains to expose core mannose residues. This modified
enzyme is then taken up by mannose receptors and is delivered to lysosomes where it
supplements the defective enzyme (58). A different way to treat Gaucher’s disease type I
patients is the »substrate reduction therapy« (SRT) that reduces cellular glycosphingo-
lipid biosynthesis. An imino sugar N-butyl-deoxynojirimycin (NB-DNJ) that inhibits ac-
tivity of the first enzyme in the glucosylating sphingolipid synthetic pathway was tested
in clinical trials and has shown to be an effective therapy (59).
Carbohydrate-based drugs for neurological diseases
Carbohydrates have also found their use in treating neurological diseases. There are
attempts to develop carbohydrate drugs for Parkinson’s disease and other neurological
indications (26). The development is initially focused on the modification of certain gly-
colipid compounds that have previously demonstrated clinical promise. Since there is
no known prevention or cure for this disease and current treatments focus only on con-
trolling the symptoms of the disease and do not retard its progression, this would be a
significant improvement.
Viral deconstructors
Carbohydrates could also be used in preventing viral invasion. It seems that even a
minor interference with sugars on the proteins of viral coats of hepatitis B and hepatitis
C viruses can have major effects. Two drugs that are supposed to do that are both vari-
ants of natural sugars and they work by inhibiting two glycoprotein-processing enzym-
es in the endoplasmatic reticulum where cells add carbohydrates to newly synthesized
proteins. When N-nonyl-deoxynojirimycin (NN-DNJ) was added to human liver cells,
glycoprocessing on the hepatitis B virus that had invaded liver cells was disrupted, and
the virus could not construct its critical component – M envelope protein (60, 61). In vitro
tests showed that inhibition of 6% of cellular glycoprocessing resulted in a more than
99% reduction in the secretion of hepatitis B virus. This change is lethal for the virus but
it has no effect on host cells.
There are also several carbohydrates that have promising in vitro biological activi-
ties against HIV (62, 63). Unfortunately, none of these molecules have yet been proven as
a good entry inhibitor in vivo.
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Transplantation rejection
When it comes to blood transfusion and transplantation, carbohydrates have the
unwanted role of a barrier. Rejection is the result of hosts having a high titer of pre-exist-
ing antibodies (probably due to the prior reaction to microbial carbohydrate structures)
against the carbohydrate epitopes. A similar problem is encountered when it comes to
xenotransplantation (64). Using animals as organ sources seems to be a good solution
for the shortage of donated human organs, but different carbohydrate patterns remain a
problem. Apes and humans, contrary to other vertebrates, do not express oligosaccha-
ride chains terminated with unfucosylated Gal(a1–3)Gal linked to glycoproteins. Since
this structure is abundant in various foods, anti-aGal antibodies are present in high con-
centrations in human serum (65), which causes hyperacute rejection of organs trans-
planted from a donor species such as pigs (66). One potential way to overcome hyper-
acute rejection is to block anti aGal antibodies or to remove them from circulation. The
pentasaccharide Gal(a1–3)Gal(b1–4)GlcNAc(b1–3)Gal(b1–4)Glc has been shown to be a
natural ligand for anti aGal antibodies and its synthetic equivalent is being evaluated in
vitro (67). Another solution to this problem would be to produce transgenic pigs that ex-
press human proteins lacking aGal structures (68).
CONCLUSIONS
With the advance in the knowledge about the roles of glycoconjugates and lectins in
the development of many diseases, glycobiology is increasingly coming into the focus of
pharmaceutical and biotechnological companies. Cancer, angiogenesis, tissue repair, ske-
letal development, cardiovascular disease, microbial infection and many more disease
processes involve carbohydrates. Thus, they are logical candidates for drug design. Car-
bohydrate based drugs appear to be safe, secure and specific. They are smaller than pro-
teins, more easily formulated for delivery into the body and more stable. As anticipated,
the demands for manufacturing therapeutic glycoconjugates will soon exceed the cur-
rent capacities, so it is expected that in the near future the pharmaceutical industry will
significantly increase its material and financial resources as well as intellectual efforts
for the purpose of extending the knowledge about the »glyco-world«. Hopefully, they
will succeed and there will be many more new »sweet« drugs in the near future.
Abbreviations and acronyms. – EPO – erythropoietin, Gal – galactose, GlcNAc – N-acetylgluco-
samine, Man – mannose, Lex – Lewis x, PSGL-1 – P-selectin glycoprotein ligand-1, gp120 – glyco-
protein 120, GPI – glycosylphosphatidylinositol, NB-DNJ – N-butyl-deoxynojirimycin, NN-DNJ –
N-nonyl-deoxynojirimycin.
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S A @ E T A K
Glikoznanost – nova smjernica u suvremenom dizajniranju lijekova
OLGA GORNIK, JERKA DUMI], MIRNA FLÖGEL I GORDAN LAUC
Glikani su najrasprostranjeniji i najraznolikiji biopolimeri prisutni u prirodi. Zbog
svojih visokospecifi~nih interakcija s fiziolo{kim receptorima sudjeluju u mnogim klju~nim
biolo{kim procesima. Svi ti procesi potencijalna su meta terapeutskih intervencija pa lije-
kovi bazirani na ugljikohidratima nalaze svoje mjesto u suvremenoj biotehnologiji i farma-
ceutskoj industriji. Razvojem glikobiologije prevladan je problem sinteze i analize glikana
pa su mnogi spojevi bazirani na ugljikohidratnim strukturama trenutno u razli~itim fa-
zama klini~kih ispitivanja. Ovaj ~lanak predstavlja glikoproteine u novom svjetlu, kao
va`ne biofarmaceutske ciljeve, daju}i pregled njihove potencijalne primjene kao terapij-
skih glikoproteina i proteoglikana, inhibitora upale, lijekova i vakcina u lije~enju tumo-
ra, inhibitora patogenih mikroorganizama i virusa, te potencijalnih sredstava u lije~enju
lizosomskih i neurolo{kih bolesti te transplantacijskih reakcija.
Klju~ne rije~i: glikoproteini, lektini, terapeutici
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